IL6R and cancer: Interestingly, using either blocking IL-6/IL-6R signaling or PD-1/PDL1 inhibitors may serve as a therapeutic target for sensitizing cancer cells to CAR-T cell treatment and restoring BCA cells to Dox treatment.